Figure 2
From: A multigene array for measurable residual disease detection in AML patients undergoing SCT
Patterns of MG-MRD expression. Level of expression of the constituent gene transcripts of the MG-MRD array in normal healthy donor control and pre-transplant AML patient peripheral blood samples. Gene expression normalized to expression of the ABL control gene. Selected threshold values are indicated by a horizontal dotted line. Two non-relapsing patients with pathologist-detectable disease pre-SCT also had 4G-MRD values above the threshold, one with both WT1 and CCNA1, the other with WT1 and PRTN3. Several patients in this historical self-described healthy donor cohort had MSLN expression above the selected threshold; MSLN is not a specific AML antigen and has also been described as being overexpressed in a variety of solid tumors.62 CCNA1, cyclin A1; MSLN, mesothelin; PRAME, preferentially expressed antigen in melanoma; PRTN3, proteinase 3; WT1, Wilms tumor 1.
